β3-adrenergic receptor activation induces TGFβ1 expression in cardiomyocytes via the PKG/JNK/c-Jun pathway

Biochem Biophys Res Commun. 2018 Sep 3;503(1):146-151. doi: 10.1016/j.bbrc.2018.05.200. Epub 2018 Jun 6.

Abstract

In heart failure, the expression of cardiac β3-adrenergic receptors (β3-ARs) increases. However, the precise role of β3-AR signaling within cardiomyocytes remains unclear. Transforming growth factor β1 (TGFβ1) is a crucial cytokine mediating the cardiac remodeling that plays a causal role in the progression of heart failure. Here, we set out to determine the effect of β3-AR activation on TGFβ1 expression in rat cardiomyocytes and examine the underlying mechanism. The selective β3-AR agonist BRL37344 induced an increase in TGFβ1 expression and the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun in β3-AR-overexpressing cardiomyocytes. Those effects of BRL37344 were suppressed by a β3-AR antagonist. Moreover, the inhibition of JNK and c-Jun activity by a JNK inhibitor and c-Jun siRNA blocked the increase in TGFβ1 expression upon β3-AR activation. A protein kinase G (PKG) inhibitor also attenuated β3-AR-agonist-induced TGFβ1 expression and the phosphorylation of JNK and c-Jun. In conclusion, the β3-AR activation in cardiomyocytes increases the expression of TGFβ1 via the PKG/JNK/c-Jun pathway. These results help us further understand the role of β3-AR signaling in heart failure.

Keywords: Cardiomyocyte; Protein kinase G; Transforming growth factor β1; c-Jun; c-Jun N-Terminal kinase; β(3)-adrenergic receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-3 Receptor Agonists / pharmacology
  • Adrenergic beta-3 Receptor Antagonists / pharmacology
  • Animals
  • Anthracenes / pharmacology
  • Carbazoles / pharmacology
  • Cells, Cultured
  • Cyclic GMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic GMP-Dependent Protein Kinases / metabolism*
  • Ethanolamines / pharmacology
  • Heart Failure / etiology
  • Heart Failure / metabolism
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • JNK Mitogen-Activated Protein Kinases / genetics
  • JNK Mitogen-Activated Protein Kinases / metabolism*
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • Propanolamines / pharmacology
  • Protein Kinase Inhibitors / pharmacology
  • RNA, Small Interfering / genetics
  • Rats
  • Receptors, Adrenergic, beta-3 / metabolism*
  • Signal Transduction / drug effects
  • Transforming Growth Factor beta1 / metabolism*

Substances

  • 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate
  • Adrenergic beta-3 Receptor Agonists
  • Adrenergic beta-3 Receptor Antagonists
  • Anthracenes
  • Carbazoles
  • Ethanolamines
  • Propanolamines
  • Protein Kinase Inhibitors
  • RNA, Small Interfering
  • Receptors, Adrenergic, beta-3
  • Tgfb1 protein, rat
  • Transforming Growth Factor beta1
  • KT 5823
  • pyrazolanthrone
  • BRL 37344
  • Cyclic GMP-Dependent Protein Kinases
  • JNK Mitogen-Activated Protein Kinases